Trade Cerus Corporation

Cyrus company is dedicated solely to protecting the world's blood supply and aims to become a prominent global blood products company. Headquartered in Concord, California, the company develops and supplies biotechand blood-protected pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. THE INTERCEPT BLOOD SYSTEM FOR PLATELETS AND PLASMA IS AVAILABLE GLOBALLY, AND REMAINS THE ONLY PATHOGEN REDUCTION SYSTEM WITH BOTH CE MARKER AND FDA APPROVAL FOR THESE TWO BLOOD COMPONENTS. The red blood cell system is subject to red blood objections for regulatory review in Europe and in the late clinical development phase in the United States. Also in the United States, the INTERCEPT blood cooling system was approved to produce a reduced pathogen compound of fibrinogen, a therapeutic product for the treatment and control of bleeding associated with fibrinogen deficiency, including massive bleeding.